Addex Therapeutics Files 6-K with Press Release
Ticker: ADXN · Form: 6-K · Filed: Aug 27, 2024 · CIK: 1574232
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Addex Therapeutics filed a 6-K on Aug 27, 2024, including a press release. Standard reporting.
AI Summary
On August 27, 2024, Addex Therapeutics Ltd. filed a Form 6-K, incorporating by reference a press release dated the same day. This filing serves as a report of a foreign private issuer and indicates that the company files annual reports under Form 20-F.
Why It Matters
This filing signals ongoing reporting activity for Addex Therapeutics as a foreign private issuer, providing investors with updated information through incorporated press releases.
Risk Assessment
Risk Level: low — The filing is a routine report of a foreign private issuer and does not contain new material financial information or significant corporate events.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- August 27, 2024 (date) — Filing and Press Release Date
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Filing Type
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer filed with the SEC, incorporating by reference a press release issued on August 27, 2024.
What is the filing date of this report?
The filing date is August 27, 2024.
What type of annual report does Addex Therapeutics file?
Addex Therapeutics files its annual reports under cover of Form 20-F.
What exhibit is incorporated by reference into this filing?
Exhibit 99.1, a press release dated August 27, 2024, is incorporated by reference.
What is the principal executive office address of Addex Therapeutics?
The principal executive office is located at Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Filing Stats: 272 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-08-27 06:05:05
Filing Documents
- f6k_082724.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-24-004935.txt ( ) — 14KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] On August 27, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. (c) Exhibit 99.1. Press release dated August 27, 2024 INCORPORATION BY REFERENCE Exhibits 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd (Registrant) Date: August 27, 2024 /s/ Tim Dyer Tim Dyer Chief Executive Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press release dated August 27, 2024